The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes

Mutations of the splicing factor–encoding gene U2AF1 are frequent in the myelodysplastic syndromes (MDS), a myeloid malignancy, and other cancers. Patients with MDS suffer from peripheral blood cytopenias, including anemia, and an increasing percentage of bone marrow myeloblasts. We studied the impact of the common U2AF1S34F mutation on cellular function and mRNA splicing in the main cell lineages affected in MDS. We demonstrated that U2AF1S34F expression in human hematopoietic progenitors impairs erythroid differentiation and skews granulomonocytic differentiation toward granulocytes. RNA sequencing of erythroid and granulomonocytic colonies revealed that U2AF1S34F induced a higher number of cassette exon splicing events in granulomonocytic cells than in erythroid cells. U2AF1S34F altered mRNA splicing of many transcripts that were expressed in both cell types in a lineage-specific manner. In hematopoietic progenitors, the introduction of isoform changes identified in the U2AF1S34F target genes H2AFY, encoding an H2A histone variant, and STRAP, encoding serine/threonine kinase receptor–associated protein, recapitulated phenotypes associated with U2AF1S34F expression in erythroid and granulomonocytic cells, suggesting a causal link. Furthermore, we showed that isoform modulation of H2AFY and STRAP rescues the erythroid differentiation defect in U2AF1S34F MDS cells, suggesting that splicing modulators could be used therapeutically. These data have critical implications for understanding MDS phenotypic heterogeneity and support the development of therapies targeting splicing abnormalities.

[1]  J. Boultwood,et al.  Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications. , 2017, Advances in biological regulation.

[2]  Mallory A. Havens,et al.  Splice-switching antisense oligonucleotides as therapeutic drugs , 2016, Nucleic acids research.

[3]  R. Kusec,et al.  Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes , 2016, Leukemia.

[4]  Michael R. Green,et al.  U2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 Pre-mRNA 3' End Formation. , 2016, Molecular cell.

[5]  Saijuan Chen,et al.  Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes , 2016, Tumor Biology.

[6]  Renata Guerra-Sá,et al.  The impact of sequence length and number of sequences on promoter prediction performance , 2015, BMC Bioinformatics.

[7]  J. Valcárcel,et al.  The pathogenicity of splicing defects: mechanistic insights into pre‐mRNA processing inform novel therapeutic approaches , 2015, EMBO reports.

[8]  V. Santini.  Anemia as the Main Manifestation of Myelodysplastic Syndromes. , 2015, Seminars in hematology.

[9]  E. Obayashi,et al.  A novel 3′ splice site recognition by the two zinc fingers in the U2AF small subunit , 2015, Genes & development.

[10]  J. Boultwood,et al.  The molecular pathogenesis of the myelodysplastic syndromes , 2015, European journal of haematology.

[11]  R. Fulton,et al.  Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo. , 2015, Cancer cell.

[12]  H. Deeg,et al.  SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. , 2015, Cancer cell.

[13]  J. Královičová,et al.  Identification of U2AF(35)-dependent exons by RNA-Seq reveals a link between 3′ splice-site organization and activity of U2AF-related proteins , 2015, Nucleic acids research.

[14]  Philip Bradley,et al.  U2AF1 mutations alter splice site recognition in hematological malignancies , 2014, bioRxiv.

[15]  Lan Lin,et al.  rMATS: Robust and flexible detection of differential alternative splicing from replicate RNA-Seq data , 2014, Proceedings of the National Academy of Sciences.

[16]  P. Datta,et al.  Oncogenic STRAP functions as a novel negative regulator of E-cadherin and p21Cip1 by modulating the transcription factor Sp1 , 2014, Cell cycle.

[17]  L. Ding,et al.  U2AF1 Mutations Alter Sequence Specificity of pre-mRNA Binding and Splicing , 2014, Leukemia.

[18]  S. Ogawa,et al.  Splicing factor mutations and cancer , 2014, Wiley interdisciplinary reviews. RNA.

[19]  Chandra Sekhar Pedamallu,et al.  A Pan-Cancer Analysis of Transcriptome Changes Associated with Somatic Mutations in U2AF1 Reveals Commonly Altered Splicing Events , 2014, PloS one.

[20]  Lior Pachter,et al.  A dynamic alternative splicing program regulates gene expression during terminal erythropoiesis , 2014, Nucleic acids research.

[21]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[22]  M. Cazzola,et al.  The genetic basis of myelodysplasia and its clinical relevance. , 2013, Blood.

[23]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[24]  B. Ko,et al.  Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression , 2013, American journal of hematology.

[25]  Larry J. Smith,et al.  TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients , 2013, Proceedings of the National Academy of Sciences.

[26]  J. Maciejewski,et al.  Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. , 2013, Blood.

[27]  Robert Gentleman,et al.  Software for Computing and Annotating Genomic Ranges , 2013, PLoS Comput. Biol..

[28]  G. Mufti,et al.  Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome , 2013, Haematologica.

[29]  J. I. Izpisúa Belmonte,et al.  Macro Histone Variants Are Critical for the Differentiation of Human Pluripotent Cells* , 2013, The Journal of Biological Chemistry.

[30]  W. Shi,et al.  The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote , 2013, Nucleic acids research.

[31]  P. Woll,et al.  Silencing of ASXL1 impairs the granulomonocytic lineage potential of human CD34+ progenitor cells , 2013, British journal of haematology.

[32]  Eda Yildirim,et al.  Xist RNA Is a Potent Suppressor of Hematologic Cancer in Mice , 2013, Cell.

[33]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[34]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[35]  U. Germing,et al.  Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts , 2012, Leukemia.

[36]  Chris Williams,et al.  RNA-SeQC: RNA-seq metrics for quality control and process optimization , 2012, Bioinform..

[37]  Claude Preudhomme,et al.  Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. , 2012, Blood.

[38]  A. Jankowska,et al.  Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. , 2012, Blood.

[39]  A. Krainer,et al.  RNA therapeutics: beyond RNA interference and antisense oligonucleotides , 2012, Nature Reviews Drug Discovery.

[40]  Li Ding,et al.  RECURRENT MUTATIONS IN THE U2AF1 SPLICING FACTOR IN MYELODYSPLASTIC SYNDROMES , 2011, Nature Genetics.

[41]  G. Garcia-Manero,et al.  SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. , 2012, Blood.

[42]  Peter J Campbell,et al.  Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms , 2011, Blood.

[43]  M. Stratton,et al.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.

[44]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[45]  M. Bitzer,et al.  Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. , 2011, Cancer research.

[46]  P. Datta,et al.  TGF-beta-dependent and -independent roles of STRAP in cancer. , 2011, Frontiers in bioscience.

[47]  E. Wang,et al.  Analysis and design of RNA sequencing experiments for identifying isoform regulation , 2010, Nature Methods.

[48]  Cole Trapnell,et al.  Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. , 2010, Nature biotechnology.

[49]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[50]  P. Bouvet,et al.  Histone variant macroH2A1 deletion in mice causes female-specific steatosis , 2010, Epigenetics & Chromatin.

[51]  Matthew D. Young,et al.  Gene ontology analysis for RNA-seq: accounting for selection bias , 2010, Genome Biology.

[52]  T. Hothorn,et al.  Histone macroH2A isoforms predict the risk of lung cancer recurrence , 2009, Oncogene.

[53]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[54]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[55]  Paul T. Spellman,et al.  GenomeGraphs: integrated genomic data visualization with R , 2009, BMC Bioinformatics.

[56]  B. Frey,et al.  Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing , 2008, Nature Genetics.

[57]  C. Zauner,et al.  Mixed‐lineage eosinophil/basophil crisis in MDS: a rare form of progression , 2008, European journal of clinical investigation.

[58]  U. Fischer,et al.  Unrip, a factor implicated in cap-independent translation, associates with the cytosolic SMN complex and influences its intracellular localization. , 2005, Human molecular genetics.

[59]  Bart De Moor,et al.  BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis , 2005, Bioinform..

[60]  Dmitri A. Nusinow,et al.  Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[61]  G. Crooks,et al.  WebLogo: a sequence logo generator. , 2004, Genome research.

[62]  S. Miyawaki,et al.  Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. , 2003, Blood.

[63]  Christopher B. Burge,et al.  Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals , 2003, RECOMB '03.

[64]  Harold L. Moses,et al.  STRAP and Smad7 Synergize in the Inhibition of Transforming Growth Factor β Signaling , 2000, Molecular and Cellular Biology.

[65]  Michael R. Green,et al.  Functional recognition of the 3′ splice site AG by the splicing factor U2AF35 , 1999, Nature.

[66]  C. Dharia,et al.  Developmental and tissue expression patterns of histone macroH2A1 subtypes , 1997, Journal of cellular biochemistry.

[67]  M. Warren,et al.  CD34+ cell expansion and expression of lineage markers during liquid culture of human progenitor cells , 1995, Stem cells.

[68]  G. Ricevuti,et al.  Leukocyte CD11/CD18 integrins: biological and clinical relevance. , 1995, Haematologica.

[69]  Michael R. Green,et al.  A factor, U2AF, is required for U2 snRNP binding and splicing complex assembly , 1988, Cell.